会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明公开
    • Methods for determining a risk to develop cancer
    • 维尔法赫恩zur Bestimmung eines Risikos,Krebs zu erkranken
    • EP2308994A1
    • 2011-04-13
    • EP10181096.8
    • 2002-03-21
    • YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    • Livneh, ZviPaz-Elizur, TamarBlumenstein, Sara
    • C12Q1/68C12P19/34C07H21/02C07H21/04
    • C12Q1/6886C12Q2600/106G01N33/574G01N2333/924G01N2333/988G01N2800/52
    • The present invention concerns a method of determining a risk of a subject to develop cancer, the method comprising determining a level of catalytic activity of a DNA repair enzyme in a biological sample of the subject, wherein said DNA repair enzyme is selected from the group consisting of 8-oxoguanine DNA glycosylase (OGG1), AP endonuclease1 (APE1), methylpurine DNA glycosylase (MFG), uracil DNA glycosylase1 (UNG1), uracil DNA glycosylase2 (UNG2), SMUG1, MBD4, mismatch-specific thymine/uracil glycosylase (TDG), enodonuclease III (NTH1), adenine-specific mismatch DNA glycosylase (MYH), 8-oxo-GTPase/8-oxodGTPase (MTH1), dUTPase (DUT), AP endonuclease2 (APE2), deoxyribose phosphate lyase (POLB) and wherein a level of said activity below a predetermined value is indicative of an increased risk of the subject to develop said cancer.
    • 本发明涉及确定受试者发展癌症的风险的方法,所述方法包括测定受试者生物样品中DNA修复酶的催化活性水平,其中所述DNA修复酶选自 (OGG1),AP内切核酸酶1(APE1),甲基嘌呤DNA糖基化酶(MFG),尿嘧啶DNA糖基化酶1(UNG1),尿嘧啶DNA糖基化酶2(UNG2),SMUG1,MBD4,错配特异性胸腺嘧啶/尿嘧啶糖基化酶 ),核酸核酸酶III(NTH1),腺嘌呤特异性错配DNA糖基化酶(MYH),8-氧代-GTP酶/ 8-氧化GTP酶(MTH1),dUTPase(DUT),AP内切核酸酶2(APE2),脱氧核糖磷酸裂解酶(POLB) 所述活性低于预定值的水平表示受试者发展所述癌症的风险增加。